Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): A phase II multicenter trial

Lung Cancer

Volumn 46, Issue 1, 2004, Pages 113-118

  Hirsh, Vera ^a   Whittom, R ^b   Desjardins, P ^c   Laberge, F ^d   Latreille, J ^c   Samson, B ^c   Langleben, A ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^c HÔPITAL CHARLES LEMOYNE   (Canada)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

Chemona ve; Days 1 and 8 administration; Docetaxel; Gemcitabine; Lower toxicity; Metastatic; Non small cell lung carcinoma; Phase II study

Indexed keywords

DOCETAXEL; GEMCITABINE; GROWTH FACTOR; NAVELBINE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HUMAN; KIDNEY FAILURE; LEG EDEMA; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; MULTICENTER STUDY; MYALGIA; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL ANALYSIS; TAXOIDS;

EID: 4444240840     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.03.007     Document Type: Article

References (27)

1. Bulzebruck H., Bopp R., Drings P., et al. New aspects in staging of lung cancer. Cancer. 70:1992;1102-1110
2. Soquet P.J., Chauvin F., Boissel J.P., et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet. 342(8862):1993;19-21
3. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995;311:899-909.
4. Rapp E., Pater J.L., Willian A., et al. Chemotherapy can prolong survival in patients with advanced non small cell lung cancer: report of a Canadian multicentre randomized trial. J. Clin. Oncol. 6:1988;633-641
5. Jaakkimainen L., Goodwin P.J., Pater J., Warde P., Murray N., Rapp E. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non small cell lung cancer. J. Clin. Oncol. 8:1990;1301-1309
6. Spiridonidis C.H., Laufman L.R., Jones J., et al. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. J. Clin. Oncol. 16:1998;3866-3873
7. Spiridonidis C.H., Laufman L.R., Carman L. Second-line chemotherapy with weekly gemcitabine (GEM) and monthly docetaxel (DOC) in patients (Pts) with non small cell lung cancer (NSCLC): a phase II study. Proc. Am. Soc. Clin. Oncol. 19:2000;503a. [abstract 1968]
8. Georgoulias V., Kouroussis C., Androulakis N., et al. Front-line treatment of advanced non small cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. J. Clin. Oncol. 17:1999;914-920
9. Rigas J.R., Rothenberg M.L., Davis T.H., et al. Phase I clinical and pharmacokinetic study of docetaxel in combination with two gemcitabine infusion schedules. Proc. Am. Soc. Clin. Oncol. 18:1999;226a. [abstract 870]
10. Denes A.E., Needles B.M., Schmidt A., et al. A comparison of two schedules of docetaxel (D) in combination with gemcitabine (G) given every other week. Proc. Am. Soc. Clin. Oncol. 19:2000;212a. [abstract 828]
11. Rizvi N.A., Spiridonidis H., Davis T.H., et al. Docetaxel and gemcitabine combinations in non small cell lung cancer. Semin. Oncol. 26(Suppl 16):1999;S27-S31
12. Rubio G., Blajman C., Capó A., et al. Docetaxel and gemcitabine in metastatic non small cell lung cancer (NSCLC). A phase II study. Preliminary feasibility report. Proc. Am. Soc. Clin. Oncol. 11:1999;522a. [abstract 2012]
13. Rebattu P., Quantin X., Morere J., et al. A phase II study of docetaxel (D) and gemcitabine (G) combination in patients (pts) with non small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 19:2000;539a. [abstract 2124]
14. Georgoulias V., Papadakis E., Alexopoulos A., et al. Platinum-based and non-platinum based chemotherapy in advanced non small cell lung cancer: a randomised multicentre trial. Lancet. 357:2001;1478-1484
15. Patel R., Keiser L.W., Justice G.R., et al. ACORN 9901: a multicenter randomized trial of docetaxel and gemcitabine versus weekly paclitaxel and gemcitabine in patients (pts) with non small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 21:2002;320a. [abstract 1276]
16. Hirsh V., Langleben A., Ayoub J., et al. Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic non small cell lung carcinoma: a phase II multicenter trial. Cancer. 92:2001;830-835
17. Hirsh V., Whittom R., Ofiara L., et al. Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC). Cancer. 97:2003;2242-2247
18. Fossella F., Pereira J.R., von Pawel J., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non small cell lung cancer: the TAX 326 Study Group. J. Clin. Oncol. 21:2003;3016-3024
19. Rudd R.M., Gower N.H., James L.E., et al. Phase III randomized comparison of gemcitabine and carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIP) in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 21:2002;292a. [abstract 1164]
20. Sederholm C. Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a phase III study by the Swedish Lung Cancer Study Group (SLCSG). Proc. Am. Soc. Clin. Oncol. 21:2002;291a. [abstract 1162]
21. Novakova L., Novakova L., Petruzelka L., et al. Gemcitabine plus cisplatin (GCis) versus gemcitabine plus carboplatin (GCarb) in patients with stage IIIB and IV non small cell lung cancer (NSCLC): final results of Czech Lung Cancer Cooperative Group phase III randomized trial. Proc. Am. Soc. Clin. Oncol. 21:2002;307a. [abstract 1225]
22. Rosell R., Gatzemeier U., Betticher D.C., et al. Phase III randomized trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non small cell lung cancer: a cooperative multinational trial. Ann. Oncol. 13:2002;1539-1549
23. Schiller J., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non small cell lung cancer. N. Engl. J. Med. 346:2002;92-98
24. Scagliotti G.V., De Marinis F., Rinaldi M., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non small cell lung cancer. J. Clin. Oncol. 20:2002;4285-4291
25. Alberola V., Camps C., Provencio M., et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus non-platinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J. Clin. Oncol. 21:2003;3207-3213
26. Greco F.A., Gray J.R., Thompson D.S., et al. Prospective randomized study of four novel chemotherapy regimens in patients with advanced non-small cell lung carcinoma: a Minnie Pearl Cancer Research Network trial. Cancer. 95:2002;1279-1285
27. Shepherd F.A., Pereira J.R., von Pawel J., et al. A phase III study of pemetrexed versus docetaxel in patients with advanced non small cell lung cancer (NSCLC) who were previously treated with chemotherapy. Lung Cancer. 41(2):2003;S4. [abstract PL-5]